The relationship between mortality and daily number of steps in type 2 diabetes.


Journal

Panminerva medica
ISSN: 1827-1898
Titre abrégé: Panminerva Med
Pays: Italy
ID NLM: 0421110

Informations de publication

Date de publication:
Sep 2023
Historique:
medline: 27 9 2023
pubmed: 1 6 2022
entrez: 31 5 2022
Statut: ppublish

Résumé

Physical activity (PA) is an established modifiable factor for the prevention of cardiovascular disease. Our objective was to assess the association of PA with mortality rates in a national sample of patients with diabetes. We analyzed a nationally representative sample from The National Health and Nutrition Examination Survey (NHANES, periods 2003-2004 and 2005-2006) that used PA Monitors. Individuals were matched for BMI, number of steps/per day and age. Three groups were created: subjects with less than 5000/steps per day (low), 5000-7500/steps per day (moderate) and more than 7500/steps per day (high levels of physical activity). All-cause mortality was ascertained through December 2015. A sample of 3072 individuals (1018 with diabetes) was analyzed. Patients with diabetes had 30% increased risk of mortality of all causes (RR: 1.298, 95% CI [1.162-1.451], P<0.001), higher levels of PA (>7500 steps/day) provided similar relative risk for subjects with diabetes compared to their controls (RR:1.256 [95% CI 0.910-1.732]). In a Poisson model adjusted for sex, history of previous cardiovascular event or cancer, ethnicity, Hb1ac, SBP, and total cholesterol to HDL ratio, patients with diabetes and moderate or high PA had an associated 44% to 80% lower risk of all-cause mortality compared to those with low PA. The subgroup of patients with diabetes and high PA had no excess of mortality compared to the general population. PA can reduce the gap for all-cause mortality, used as an index of cardiovascular fitness and a clinical tool for the assessment of mortality risk.

Sections du résumé

BACKGROUND BACKGROUND
Physical activity (PA) is an established modifiable factor for the prevention of cardiovascular disease. Our objective was to assess the association of PA with mortality rates in a national sample of patients with diabetes.
METHODS METHODS
We analyzed a nationally representative sample from The National Health and Nutrition Examination Survey (NHANES, periods 2003-2004 and 2005-2006) that used PA Monitors. Individuals were matched for BMI, number of steps/per day and age. Three groups were created: subjects with less than 5000/steps per day (low), 5000-7500/steps per day (moderate) and more than 7500/steps per day (high levels of physical activity). All-cause mortality was ascertained through December 2015.
RESULTS RESULTS
A sample of 3072 individuals (1018 with diabetes) was analyzed. Patients with diabetes had 30% increased risk of mortality of all causes (RR: 1.298, 95% CI [1.162-1.451], P<0.001), higher levels of PA (>7500 steps/day) provided similar relative risk for subjects with diabetes compared to their controls (RR:1.256 [95% CI 0.910-1.732]). In a Poisson model adjusted for sex, history of previous cardiovascular event or cancer, ethnicity, Hb1ac, SBP, and total cholesterol to HDL ratio, patients with diabetes and moderate or high PA had an associated 44% to 80% lower risk of all-cause mortality compared to those with low PA.
CONCLUSIONS CONCLUSIONS
The subgroup of patients with diabetes and high PA had no excess of mortality compared to the general population. PA can reduce the gap for all-cause mortality, used as an index of cardiovascular fitness and a clinical tool for the assessment of mortality risk.

Identifiants

pubmed: 35638241
pii: S0031-0808.22.04732-2
doi: 10.23736/S0031-0808.22.04732-2
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

335-342

Auteurs

Denis Charles (D)

CRIEF, University of Poitiers, Poitiers, France.
Research and Development Department SCOR, Paris, France.

Pierre Sabouret (P)

Department of Cardiology, Heart Institute, Pitié Salpêtrière Hospital (AP-HP), Sorbonne University, Paris, France.

Antoine Moll (A)

Research and Development Department SCOR, Paris, France.

Manuel Plisson (M)

Research and Development Department SCOR, Paris, France.

Khurram Nasir (K)

Division of Cardiovascular Prevention and Wellness, Houston Methodist DeBakey Heart and Vascular Institute, Houston, TX, USA.

Giuseppe Biondi-Zoccai (G)

Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University, Latina, Italy.
Mediterranea Cardiocentro, Naples, Italy.

Martha Gulati (M)

Department of Cardiology, Cedars Sinai Heart Institute, Los Angeles, CA, USA.

Deepak L Bhatt (DL)

Brigham and Women's Hospital, Heart and Vascular Center, Harvard Medical School, Boston, MA, USA.

Marinos Fysekidis (M)

Research and Development Department SCOR, Paris, France - drfysekidis.marinos@gmail.com.
Department of Diabetology, Private Hospital of East Paris, Aulnay sous Bois, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH